Progressive Osseous Heteroplasia is not an Autosomal Dominant Trait but Reflects Superimposed Mosaicism in Different GNAS Inactivation Disorders

Abstract

Progressive osseous heteroplasia (POH) is a rarely occurring genetic condition characterized by severe segmental ossification involving the skin and deep connective tissues including the muscles. So far, the disorder is generally described as an autosomal dominant trait. By contrast, the following arguments are in favor of the alternative concept that POH should rather be taken as a non-specific segmental manifestation of different GNAS inactivation disorders such as Albright hereditary osteodystrophy (AHO) with hormone resistance, AHO without hormone resistance, and osteomatosis cutis. Presently, POH has got its own OMIM number 166350 but this is obviously wrong because the disorder does not reflect heterozygosity for a GNAS mutation. Conversely, the disorder is most likely due to an early event of postzygotic loss of heterozygosity with loss of the corresponding wild-type allele. This alternative concept, as proposed in 2016, offers a plausible explanation for the following features of POH. Familial occurrence is usually absent. POH is usually observed in families with one of the three GNAS inactivation disorders as mentioned above. Mosaicism is suggested by the pronounced segmental manifestation of POH and by its lateralization. Some patients have, in addition to POH, bilaterally disseminated features of osteomatosis cutis or AHO, and other patients have family members with one of these nonsegmental disorders. Remarkably, POH tends to appear much earlier than the nonsegmental GNAS inactivation disorders. – Molecular support of the concept was documented in a superficial variant of POH called ‘plate-like osteoma cutis’. In several other autosomal dominant skin disorders, molecular corroboration of the theory of superimposed mosaicism has been provided. – For all of these reasons, it is unlikely that POH can further be taken as a distinct autosomal dominant trait. Generation of more molecular data in multiple cases of POH occurring in GNAS inactivation disorders will be crucial to corroborate the proposed concept.

Keywords: GNAS inactivation disorders, loss of heterozygosity, mosaic skin disorder, superimposed mosaicism

I read with great interest the well-documented report of Drs. Sahu and coworkers on unilateral “progressive osseous heteroplasia (POH)” in a 3-year-old boy.[1] Initial cutaneous calcifications were noted at the age of 2 months. Subsequently, the boy developed pronounced ossifications in the dermis and subcutis corresponding to the area of segmental cutaneous involvement. The authors correctly describe the view, as presently promulgated worldwide, that POH is a distinct autosomal dominant disorder caused by GNAS inactivating mutations in a heterozygous state.[2–5]

As opposed to this and apart from the beaten path, I’m arguing that POH is not a Mendelian trait.[6] Most likely, it represents a superimposed mosaic manifestation of at least three different autosomal dominant GNAS inactivation disorders in the form of Albright hereditary osteodystrophy (AHO) with hormone resistance (OMIM 103580), AHO without hormone resistance (OMIM 612463), and osteoma cutis (OMIM 166350).[5]

Historical note on the naming of superimposed mosaicism

The concept of superimposed mosaicism was first proposed as a hypothesis in 1996.[7] Initially, it was called “type 2 segmental manifestation”,[8] and later “type 2 segmental...
mosaicism”.[9] Recently, the idea was renamed as “superimposed mosaicism”.[10] The word ‘segmental’ seems dispensable because all manifestations of superimposed mosaicism occur in a segmental form.

**Description of the genetic concept**

In autosomal dominant skin disorders, a well-known form of mosaic involvement is simple segmental mosaicism caused by a very early postzygotic new mutation in an otherwise healthy embryo [Figure 1]. By contrast, in an embryo being heterozygous for such a disorder there may occur, at a very early developmental stage, a postzygotic event of loss of heterozygosity (LOH) resulting in loss of the corresponding wild-type allele, which gives rise to a homozygous or hemizygous cell. The segmental outgrowth of the arising mutant clone results in a pronounced mosaic involvement being superimposed on the nonsegmental heterozygous phenotype of the same disorder [Figure 1].[8]

**Molecular data supporting the concept of superimposed mosaicism**

Molecular findings in support of this theory have already been documented in a superficial variant of POH called “plate-like osteoma cutis”[11] and in a mouse model.[12,13] Moreover, molecular proof of principle was provided in several other autosomal domain skin disorders [Table 1].

**The concept of superimposed mosaicism applied to the report of Drs. Sahu and coworkers**

The statement of Drs. Sahu et al.[1] that “POH is caused by heterozygous inactivating mutations of GNAS” is in line with the majority of the presently available literature,[2‑5, 23‑25] but it is most likely wrong. Conversely, POH appears to be caused by an early postzygotic event of loss of heterozygosity at the GNAS locus, resulting in superimposed segmental biallelic mosaicism.[6] Moreover, the diagnostic criterion of “evidence for paternal inheritance” is questionable because maternal inheritance of POH has also been documented.[26,27]

The authors report that there was no history of “similar lesions” in the family members. It should be borne in mind that the patient’s relatives should not be examined for similar lesions but for the presence of mild, inconspicuous disseminated features of AHO or osteoma cutis.[20] In my view, this little boy will most likely develop, in his later life, the disseminated skin lesions of osteoma cutis,[29‑31] but AHO cannot be excluded as yet.

Besides, the proposed concept would offer a plausible explanation for some diagnostic criteria of POH mentioned by the authors, such as the lateralized involvement and “age at onset younger than 1 year”. [1]

**Conclusive Remarks**

Since 2016 when the concept of superimposed mosaicism of POH was proposed,[6] no additional supporting molecular findings were published. Hence, in view of the limited human data[11] the concept cannot be taken as proven, which is why the following alternate hypotheses should also be taken into account. An as yet unknown modifier gene may explain why several patients have POH in addition to pseudohypoparathyroidism type 1A.[32] Moreover, epigenetic conditioning may affect one or several segments of the body, resulting in POH.[27,33]

On the other hand, an etiological relationship with genomic imprinting, which plays a major role in the severity of pseudohypoparathyroidism type 1A, is rather unlikely because POH has been described in all of the three types of GNAS inactivation disorders as known so far.[6]

Generation of more molecular data in multiple cases of POH occurring in GNAS inactivation disorders will be crucial to proving the present hypothesis. For the time being, however, POH should not simply be regarded as an autosomal dominant trait reflecting heterozygosity, but the alternative theory of superimposed mosaicism should also be considered.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

---

**Table 1: Autosomal dominant skin disorders with superimposed mosaic manifestation confirmed at the molecular level**

| Disorder                        | Reference(s)       |
|---------------------------------|---------------------|
| Darier disease                  | [44]               |
| Hailey-Hailey disease           | [15]               |
| Glomangiomatosis                | [16]               |
| Gorlin syndrome                 | [47]               |
| Legius syndrome                 | [48]               |
| Neurofibromatosis I             | [19]               |
| Osteomatisis cutis              | [11]               |
| Porokeratosis (DSAP and plaque type) | [20]           |
| PTEN hamartoma syndrome         | [21,22]            |
References

1. Sahu K, Rout AN, Mohapatra L, Mohanty P. Progressive osseous heteroplasia: A rare case report. Indian Dermatol Online J 2020;11:604-6.

2. Kaplan FS, Shore EM. Perspective: Progressive osseous heteroplasia. J Bone Miner Res 2000;15:2084-94.

3. Shore EM, Ahn J, Jan de Beur S, Li M, Xu M, Gardner RJ, et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002;346:99-106.

4. Schrander DE, Welting TJ, Caron MM, Schrander JJ, van Rhijn LW, Körver-Keularts I, et al. Enchondral ossification in a case of progressive osseous heteroplasia in a young female child. J Pediatr Orthop B 2014;23:477-84.

5. Online Mendelian Inheritance in Man (OMIM). Available from: http://www3.ncbi.nlm.nih.gov/Omim/. [Last accessed on 2020 Jul 20].

6. Happle R. Progressive osseous heteroplasia is not a Mendelian trait but a type 2 segmental manifestation of GNAS inactivation disorders: A hypothesis. Eur J Med Genet 2016;59:290-4.

7. Happle R. Segmental forms of autosomal dominant skin disorders: Different types of severity reflect different states of zygosity. Hum Genet 1996;66:241-2.

8. Happle R. A rule concerning the segmental manifestation of autosomal dominant skin disorders: Review of clinical examples providing evidence for dichotomous types of severity. Arch Dermatol 1997;133:1505-9.

9. Happle R. The categories of cutaneous mosaicism: A proposed classification. Am J Med Genet 2016;170A: 452-9.

10. Happle R, Torrelo A. Superimposed mosaicism in tuberous sclerosis complex: A key to understanding all of the manifold manifestations? J Eur Acad Dermatol Venereol 2020. doi: 10.1111/jdv. 16603.

11. Huh JY, Kwon MJ, Seo KY, Kim MK, Chae KY, et al. Novel nonsense GNAS mutation in a 14-month-old boy with plate-like osteoma cutis and medulloblastoma. J Dermatol 2014;41:319-21.

12. Regard JP, Malhotra D, Grozdenovic-Jeremic J, Josey M, Chen M, Weinstein LS, et al. Activation of hedgehog signaling by loss of GNAS causes heterotopic ossification. Nat Med 2013;19:1505-12.

13. Cairns DM, Pignolo RJ, Uchimura T, Brennan TA, Lindborg CM, Xu M, et al. Somitic disruption of GNAS in chick embryos mimics progressive osseous heteroplasia. J Clin Invest 2013;123:3624-33.

14. Fölster-Holst R, Nellen RG, Jensen JM, Poblete-Gutierrez P, Steijlen PM, Schwarz T, et al. Molecular genetic support for the rule of dichotomy in type 2 segmental Darier disease. Br J Dermatol 2012;166:464-6.

15. Poblete-Gutiérrez P, Wiedenholt T, König A, Jugert FK, Marquardt Y, Rübben A, et al. Allelic loss underlies type 2 segmental Hailey-Hailey disease, providing molecular confirmation of a novel genetic concept. J Clin Invest 2004;114:1467-74.

16. Amyere M, Aerts V, Brouillard P, McIntyre BAS, Duhoux FP, Wassef M, et al. Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet 2013;92:188-96.

17. Torrelo A, Hernandez-Martin A, Bueno E, Colmenero I, Rivera I, Requena L, et al. Molecular evidence of type 2 mosaicism in Gorlin syndrome. Br J Dermatol 2013;169:1342-5.

18. Brems H, Chinara M, Sahbatou M, Denayer E, Tanuguchi K, Kato R, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis-like phenotype. Nat Genet 2007;39:1120-6.

19. Steinmann K, Kluwe I, Friedrich RE, Mautner VF, Cooper DN, Kehrer-Sawatzki H. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated pleomorphic neurofibroma. J Invest Dermatol 2009;129:615-21.

20. Atzmony L, Khan HM, Lim YH, Paller AS, Levinsohn JL, Holland KE, et al. Second-hit, postzygotic PMVK and MVD mutations in linear porokeratosis. JAMA Dermatol 2019;155:548-55.

21. Loffeld A, McLellan NJ, Cole T, Payne SJ, Fricker D, Moss C. Epidermal naevus in Proteus syndrome showing loss of heterozygosity for an inherited PTEN mutation. Br J Dermatol 2006;154:1194-8.

22. Happle R. Type 2 segmental Cowden disease vs. Proteus syndrome. Br J Dermatol 2007;156:1089-90.

23. Adegbite NS, Xu M, Kaplan FS, Shore EM, Pignolo RJ. Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am J Med Genet 2008;146A:1788-96.

24. Schimmel RJ, Pasmans SG, Xu M, Stadhouders-Keet SA, Shore EM, Kaplan FS, et al. GNAS-associated disorders of cutaneous ossification: Two different clinical presentations. Bone 2010;46:868-72.

25. Singh GK, Verma V. Progressive osseous heteroplasia in a 10-year-old male child. Indian J Orthop 2011;45:280-2.

26. Ahmed SF, Barr DGD, Bonthron DT. GNAS1 mutations and progressive osseous heteroplasia. N Engl J Med 2002;346:1669-71.

27. Lin MH, Numbenjaporn N, Germain-Lee EL, Pitukcheewanont P. Progressive osseous heteroplasia as an isolated entity or overlapping with Albright hereditary osteodystrophy. J Pediatr Endocrinol Metab 2015;28:911-8.

28. Eddy MC, Jan De Beur SM, Yandow SM, McAlister WH, Shore EM, Kaplan FS, et al. Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. J Bone Min Res 2000;15:2074-83.

29. Gardner RJ, Yun K, Craw SM. Familial ectopic calcification. J Med Genet 1988;25:113-7.

30. Rosenfeld SR, Kaplan FS. Progressive osseous heteroplasia in male patients: Two new case reports. Clin Orthop Relat Res 1995;317:243-5.

31. Elli FM, Barbieri AM, Bordogna P, Ferrarei P, Bufo R, Ferrante E, et al. Screening of GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: First Italian series. Bone 2013;56:276-80.

32. Faust RA, Shore EM, Stevens CE, Xu M, Shah S, Phillips CD, et al. Progressive osseous heteroplasia in the face of a child. Am J Med Genet 2003;118A: 71-5.

33. Jüppner H. The genetic basis of progressive osseous heteroplasia. N Engl J 2002;346:128-30.